Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649258 · ClinicalTrials.gov registry record · Phase 1
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01649258 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 29 participants.
The verdict
NCT01649258, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This clinical trial studies how well fosaprepitant dimeglumine and granisetron transdermal system work in preventing nausea and vomiting in patients with breast cancer undergoing chemotherapy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy
Interventions
- OTHER laboratory biomarker analysis
- DRUG granisetron transdermal system
- DRUG fosaprepitant dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-09-04 |
| Est. Completion | 2017-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01649258
The ClinicalTrials.gov registry entry for NCT01649258 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01649258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01649258 about?
NCT01649258 is a clinical study titled "Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy". This clinical trial studies how well fosaprepitant dimeglumine and granisetron transdermal system work in preventing nausea and vomiting in patients with breast cancer undergoing chemotherapy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy
What is the current status of trial NCT01649258?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-09-04. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT01649258?
The interventions under investigation include: laboratory biomarker analysis (OTHER), granisetron transdermal system (DRUG), fosaprepitant dimeglumine (DRUG).
Who is sponsoring clinical trial NCT01649258?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.